- Trial phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and launching (FDA accelerated approval July 2025; EU conditional approval April 2025)
- Why 4/10
- Lynozyfic received FDA accelerated approval on July 2, 2025, and EU conditional approval in April 2025, the defining binary catalysts have passed. No new PDUFA or pivotal readout date is scheduled within the next ~12 months. The Phase 3 confirmatory trial (LINKER-MM3) is ongoing but topline timing is unspecified. Lynozyfic is also a small contributor (~$600M potential peak per BMO estimates) within Regeneron's $14B+ diversified revenue base, so even a major label expansion would be incremental rather than transformative.
Lynozyfic is already approved and launching, so there's no binary event to trade. Investors should watch script trends and quarterly revenue disclosures for commercial uptake trajectory. The more relevant catalysts for REGN stock are the Dupixent expansion, EYLEA HD performance, and broader pipeline readouts, not Lynozyfic individually.
Price Chart
Executive Summary
Lynozyfic (linvoseltamab) is Regeneron's BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma, approved by the FDA via accelerated pathway in July 2025 and conditionally approved in the EU in April 2025. It achieved a 70% objective response rate in the pivotal LINKER-MM1 trial and offers a dosing convenience edge, patients can transition from weekly to monthly IV infusions after 24 weeks. However, it enters a crowded market dominated by J&J's Tecvayli (approved 2022, $549M 2024 sales) and Pfizer's Elrexfio ($133M 2024 sales). For Regeneron, a diversified $14B-revenue biotech where Dupixent is the primary growth engine, Lynozyfic is a commercially nice addition but not a needle-moving catalyst.
How It Works
Lynozyfic is a bispecific antibody, a Y-shaped immune protein with two different "arms." One arm grabs onto a patient's T-cells (immune soldiers) and the other arm grabs onto multiple myeloma cancer cells, physically bridging them together. This forces the T-cell to attack and kill the cancer cell. It's like a molecular handcuff that locks cancer cells to the immune cells that destroy them.
Trial Status
FDA accelerated approval was based on the Phase 1/2 LINKER-MM1 trial (NCT03761108) which showed a 70% objective response rate and 45% complete response or better in 80 heavily pretreated patients. A Phase 3 confirmatory trial (LINKER-MM3) is ongoing, comparing linvoseltamab monotherapy vs. elotuzumab+pomalidomide+dexamethasone in relapsed/refractory multiple myeloma. Additional trials include LINKER-MM2 (combination therapy) and LINKER-MM4 (newly diagnosed setting).
The Two-Sided Case
Upcoming Catalysts
- Quarterly Lynozyfic sales disclosures in Regeneron earnings reports (next: Q2 2026)
- Phase 3 LINKER-MM3 confirmatory trial topline readout (date not specified)
- Potential label expansion data from LINKER-MM2 (combination therapy) and LINKER-MM4 (newly diagnosed) trials
- European launch revenue contribution in coming quarters
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report